AllSquare Wealth Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

AllSquare Wealth Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-546	Closed	-$44K	–	546
2022 Q2	$44K	Hold	546	–	–	0.03%	211
2022 Q1	$57K	Buy	546 +51	+10%	+$4.97K	0.03%	212
2021 Q4	$53K	Sell	495 -90	-15%	-$9.82K	0.03%	217
2021 Q3	$64K	Hold	585	–	–	0.04%	195
2021 Q2	$55K	Sell	585 -16	-3%	-$1.47K	0.03%	222
2021 Q1	$55K	Buy	+601	New	+$50.7K	0.03%	218

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

AllSquare Wealth Management's HZNP Position: Q3 2022 in Review

AllSquare Wealth Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 546 shares — an estimated $44K sold.

AllSquare Wealth Management first reported a position in HZNP in Q1 2021 and held it in 6 quarters. The position peaked at $64K in Q3 2021. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

AllSquare Wealth Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
AllSquare Wealth Management sold 546 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $44K.
AllSquare Wealth Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021 and held it in 6 quarters.
AllSquare Wealth Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $64K in Q3 2021.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on AllSquare Wealth Management's 13F filing for Q3 2022, filed 1 Nov 2022.